

シンポジウム Symposia

Monday, 28 March 10:50 ~ 12:00 / 13:15 ~ 17:15

Plenary Lecture: Room V Annex Hall at PACIFICO Yokohama
Invited Poster Presentation: Exhibition Hall AB

国際創薬シンポジウム ISMS

International Symposium for Medicinal Sciences

Chairman: Yuusaku YOKOYAMA (The Pharmaceutical Society of Japan)

10:50 ~ 10:55

Opening Remark

Executive Director of the Pharmaceutical Society of Japan Yuusaku YOKOYAMA

11:00 ~ 12:00

Plenary Lecture 1

Chairman: Shionogi & Co., Ltd. Tsuneaki SAKATA

ISMS-PL01 Sofosbuvir: A Breakthrough Curative Therapy for the Treatment of HCV

Arbutus Biopharma, Inc Michael J SOFIA

13:15 ~ 14:15

Plenary Lecture 2

Chairman: Tokushima University Akira OTAKA

ISMS-PL02 Allosteric Modulation of GPCRs: Leveraging Signal Bias

Vanderbilt Center for Neuroscience Drug Discovery Craig W. LINDSLEY

14:20 ~ 17:15

Invited Poster Presentation

14:20 ~ 15:40

Short Presentation for Invited Poster Presentation

15:45 ~ 17:15

28AB-ISMS01 ~ 28AB-ISMS36

Poster Presentation

Discussion Odd Number: 15:45 ~ 16:30

Even Number: 16:30 ~ 17:15

28AB-ISMS01 Rejuvenating the Motor Driven Cargo Transport Impaired by Proteotoxicity

○Sanjib BHATTACHARYYA¹ (¹Tohoku University)

28AB-ISMS02 Novel Organic Reagents Suitable for Drug Discovery—Aminomethyl and Alkoxyethyl Trifluoroborate

○Keigo TANAKA¹, Norio MURAI¹, Masayuki MIYANO¹, Masahiro YONAGA¹ (¹Eisai Co., Ltd)

28AB-ISMS03 Tissue Distribution of Teneligliptin in Rats and Comparisons with Data Reported for Other Dipeptidyl Peptidase-4 Inhibitors

○Yoshinobu NAKAMARU¹, Fumihiko AKAHOSHI¹, Hiroaki IJIMA², Noriko HISANAGA¹, Atsuhiko KAWAGUCHI¹, Masayuki SUZUKI¹, Toshiyuki KUME¹ (¹Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, ²Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation)

28AB-ISMS04 Lenvatinib Suppresses Angiogenesis Driven by VEGF and FGF through the Inhibition of both VEGFR and FGFR Signaling Pathways

○Kenji ICHIKAWA¹, Saori WATANABE-MIYANO¹, Yusuke ADACHI¹, Yuji YAMAMOTO¹, Yoichi OZAWA¹, Yasuhiro FUNAHASHI¹, Kiyoshi OKAMOTO², Kenichi NOMOTO³, Junji MATSUI¹ (¹Eisai Co., Ltd., Tsukuba, Japan, ²Eisai Co., Ltd., Tokyo, Japan ³Eisai Co., Ltd., Woodcliff Lake, NJ, USA)

- 28AB-ISMS05 Identification of Predictive Gene Expression Signatures Associated with the Therapeutic Effects of Infliximab, Tocilizumab and Abatacept in Rheumatoid Arthritis
 ○Hiroshi IJIMA¹, Seiji NAKAMURA¹, Katsuya SUZUKI², Yuko HATA¹, Chun Ren LIM¹, Yohei ISHIZAWA¹, Hideto KAMEDA³, Koichi AMANO⁴, Kenichi MATSUBARA¹, Ryo MATOBA¹, Tsutomu TAKEUCHI²
 (¹DNA Chip Research Inc., ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, ³Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, ⁴Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University)
- 28AB-ISMS06 Androstamine A, a New Antitumor Agent for Castration Resistant Prostate Cancer
 ○Yohko YAMAZAKI¹, Tohru MASUDA¹, Isao MOMOSE¹, Manabu KAWADA^{1,2}, Akio NOMOTO³, Masakatsu SHIBASAKI³ (¹Institute of Microbial Chemistry (BIKAKEN), Numazu, ²Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, ³Institute of Microbial Chemistry (BIKAKEN))
- 28AB-ISMS07 Big Data Visualization and Analysis of HTS and Broad Kinase Panel Profiling Using “Elpis Map” as a Novel User-friendly Application
 ○Hiromu EGASHIRA¹, Masakuni KURONO¹, Hiroshi KOHNO¹, Katsura YAMATSUTA¹, Jun TAKEUCHI¹, Minoru NISHIZAKI¹ (¹Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd.)
- 28AB-ISMS08 Discovery of Potent, Liver-Selective Stearoyl-CoA Desaturase-1 (SCD1) Inhibitors, Thiazole-4-acetic Acid Derivatives for the Treatment of Diabetes, Hepatic Steatosis and Obesity
 ○Tetsuya IIDA¹, Minoru UBUKATA¹, Ikuo MITANI¹, Yuichi NAKAGAWA¹, Katsuya MAEDA¹, Hiroto IMAI¹, Yosuke OGOSHI¹, Takahiro HOTTA¹, Shohei SAKATA¹, Ryuhei SANNO¹, Hisayo MORINAGA¹, Tamotsu NEGORO¹, Shinichi OSHIDA¹, Masahiro TANAKA¹, Takashi INABA¹ (¹Central Pharmaceutical Research Institute, Japan Tobacco Inc.)
- 28AB-ISMS09 An Introduction to Excellent Center for Drug Discovery (ECDD), Mahidol University, Thailand
 ○Suparek BORWORNPIYO^{1,2} (¹Excellent Center for Drug Discovery (ECDD), Mahidol University, ²Stem Cell and Gene Therapy Research Unit, Department of Biotechnology, Faculty of Science, Mahidol University)
- 28AB-ISMS10 Development of Functional Monoclonal Antibodies Targeting at GPCR for Drug Discovery
 ○Yuji URUSHIBATA¹, Tomoko SHIMIZU¹, Kazuyo FUJIKAWA¹, Masahiko SHINAGAWA¹, Masako SASAKI¹, Saya KURIBAYASHI¹, Kiyoshi TAKAYAMA¹ (¹NB Health Laboratory Co. Ltd.)
- 28AB-ISMS11 Anti Tumor Activity of Geraniin in Osteosarcoma Cells
 ○Daisuke TATSUDA¹, Isao MOMOSE², Shun-ichi OHBA², Yoji UMEZAWA³, Manabu KAWADA^{1,2}, Akio NOMOTO³, Masakatsu SHIBASAKI³ (¹Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, ²Institute of Microbial Chemistry (BIKAKEN), Numazu, ³Institute of Microbial Chemistry (BIKAKEN))
- 28AB-ISMS12 Detection of Direct Binding Interaction between Lenvatinib and Receptor Tyrosine Kinases by Chemical Probe-based Approach
 ○Noboru YAMAMOTO¹, Takayuki KIMURA¹, Megumi IKEMORI-KAWADA¹, Hiroshi KAMIYAMA¹, Akihiko YAMAMOTO¹, Yoshihiko KOTAKE¹, Yasutaka TAKASE¹, Yasuhiro FUNAHASHI¹, Yoshiya ODA¹ (¹Eisai Co., Ltd)
- 28AB-ISMS13 Novel Approach for Oligonucleotide Therapeutics Development Focused on Manufacturing and Structure Improvement
 ○Hideaki SATO¹, Akihiro OTA¹, Hirokazu NANKAI¹, Kazuhiko YUYAMA¹ (¹GeneDesign, Inc.)
- 28AB-ISMS14 Therapeutic Aptamer Discovery
 ○Yosuke NONAKA¹, Hisako IKEDA¹, Satoshi FUTAKAWA¹, Masatoshi FUJIWARA¹, Shin MIYAKAWA¹, Yoshikazu NAKAMURA¹ (¹RIBOMIC Inc.)

- 28AB-ISMS15 Discovery of Novel 2',4'-dimethyl-[4,5'-bithiazol]-2-yl Amino Derivatives as Orally-Bioavailable TRPV4 Antagonist for the Treatment of Pain
 ○Naoki TSUNO¹, Akira YUKIMASA¹, Osamu YOSHIDA¹, Shinji SUZUKI¹, Hiromi NAKAI¹, Tomoyuki OGAWA¹, Motohiro FUJII¹, Kenji TAKAYA¹, Azusa NOZU², Yusuke ICHIHASHI¹, Takatsugu INOUE¹, Tatsuhiko UENO¹, Hiroki YAMAGUCHI¹, Naotake KOBAYASHI¹, Hidetoshi MATSUDA³, Satoko FUNAKI⁴, Natsue YAMANADA¹, Miki TANIMURA¹, Yoko NISHIMURA⁴, Tetsuji ITO⁴, Daiki NAGAMATSU⁴, Shinya HISAKAWA⁴, Toshiyuki ASAKI¹, Narumi HORITA³, Miyuki YAMAMOTO¹, Mikie HINATA¹, Masahiko SOGA¹, Masayuki IMAI⁵, Yasuhide MORIOKA¹, Toshiyuki KANEMASA¹, Gaku SAKAGUCHI⁵, Yasuyoshi ISO¹ (¹Discovery Research Laboratory for Core Therapeutic Areas, Shionogi & Co., Ltd., ²Discovery Research Laboratory for Innovative Frontier Medicines, Shionogi & Co., Ltd., ³Shionogi Techno Advance Research Co., Ltd., ⁴Research Laboratory for Development, Shionogi & Co., Ltd., ⁵Pharmaceutical Research Division, Shionogi & Co., Ltd.)
- 28AB-ISMS16 Natural Lipopeptide Antibiotic Tripropeptin C Revitalizes and Synergistically Potentiates the Activity of Beta-Lactams against Methicillin-Resistant *Staphylococcus aureus*
 ○Hideki HASHIZUME¹, Yoshiaki TAKAHASHI¹, Shigeko HARADA¹, Masayuki IGARASHI¹, Akio NOMOTO¹ (¹Institute of Microbial Chemistry (BIKAKEN))
- 28AB-ISMS17 Site-specific Incorporation of Unnatural Amino Acids and Cell-free Synthesis of Proteins toward Application to Antibodies and Antigens
 ○Hiroyuki KATO¹, Tatsuo YANAGISAWA¹, Mitsuo KURATANI¹, Tetsuya HORI¹, Wataru NISHII¹, Takaho TERADA¹, Shingo SAITO¹, Tomoko NAKAYAMA¹, Takashi UMEHARA², Kensaku SAKAMOTO², Shigeyuki YOKOYAMA¹ (¹RIKEN Structural Biology Laboratory, ²RIKEN Center for Life Science Technologies (CLST))
- 28AB-ISMS18 Best-in-Class ALK Inhibitor: Alectinib
 ○Yuko AOKI¹, Tomohiro TANAKA¹, Nobuhiro OIKAWA¹, Hiroshi SAKAMOTO¹ (¹Chugai Pharmaceutical Co. LTD)
- 28AB-ISMS19 Module Technology for Oncology Drug Discovery
 ○Masakazu FUKUSHIMA¹, Kenzo IIZUKA¹, Chung ZHANG¹, Cheng JIN¹, Kiyoshi ESHIMA¹ (¹Delta-Fly Pharma, Inc.)
- 28AB-ISMS20 Preclinical Antitumor Activity of ASP5878, a Novel Inhibitor of FGFR1, 2, 3 and 4, in FGF19-expressing Hepatocellular Carcinoma
 Takashi FUTAMI¹, Hidetsugu OKADA¹, Rumi KIHARA¹, Tatsuya KAWASE¹, Ayako NAKAYAMA¹, Tomoyuki SUZUKI¹, Minoru KAMEDA¹, Nobuaki SHINDOH¹, Tadashi TERASAKA¹, Masaaki HIRANO¹, Sadao KUROMITSU¹ (¹Drug Discovery Research, Astellas Pharma Inc.)
- 28AB-ISMS21 Fast Identification of Novel HGK Inhibitors via Click Chemistry
 ○Takayuki IRIE¹, Ikuo FUJII², Masaaki SAWA¹ (¹Research and Development, Carna Biosciences, Inc., ²Department of Biological Science, Graduate School of Science, Osaka Prefecture University)
- 28AB-ISMS22 Identification and Optimization of a Series of Tetrahydrobenzotriazoles as Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulators that Improve Performance in a Preclinical Model of Cognition
 ○Tomoyuki SHIBUGUCHI¹, John M ELLARD², Andrew MADIN², Oliver PHILIPS², Mark HOPKIN², Scott HENDERSON², Louise BIRCH², Desmond O'CONNOR², Tohru ARAI¹, Kazuma TAKASE¹, Louise MORGAN², David REYNOLDS², Sonia TALMA², Eimear HOWLEY², Ben POWNEY², Jane E GARTLON², Lee A DAWSON², Luis CASTRO², Peter J ATKINSON² (¹Eisai Co., Ltd, Tsukuba Research Laboratories, ²Eisai Limited, European Knowledge Centre)
- 28AB-ISMS23 Identification of Anti-Neuroinflammatory Agent Effective in Alzheimer's Disease Animal Model
 Wei ZHOU¹, Guifa ZHONG¹, Xiurong RAO¹, Shaogao ZENG¹, Tianyan CHI¹, Libo ZOU¹, Wenhui HU¹ (¹Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences)
- 28AB-ISMS24 Hybrid Molecules of β -Carboline and Bis(hydroxymethyl)pyrrole with Topoisomerase I/II Inhibitory and DNA Cross-linking Activities Are Potent Anticancer Agents
 ○Te-Chang LEE¹, Sue-Ming CHANG¹, Ming-Hsi WU¹, Chi-Wei CHEN¹, Tsann-Long SU¹ (¹Institute of Biomedical Sciences, Academia Sinica)
- 28AB-ISMS25 Discovery of a Potent and Orally Bioavailable GPR40 Agonist DS-1558
 ○Rieko TAKANO¹, Masao YOSHIDA¹, Masahiro INOUE¹, Takeshi HONDA¹, Ryutaro NAKASHIMA¹, Koji MATSUMOTO¹, Tatsuya YANO¹, Tsuneaki OGATA¹, Nobuaki WATANABE¹, Masakazu HIROUCHI¹, Shuichiro ITO², Tomoko YONEYAMA², Takako KIMURA², Narihiro TODA¹ (¹Daiichi Sankyo Co., Ltd., ²Daiichi Sankyo RD Novare Co., Ltd.)

- 28AB-ISMS26 Establishment and Application of Novel Hairless Highly Immunodeficient Mice
 ○Ryusho KARIYA¹, Kouki MATSUDA¹, Yoriko TAKAHASHI¹, Seiji OKADA¹ (¹Division of Hematopoiesis, Center for AIDS Research and Graduate School of Medical Sciences, Kumamoto University)
- 28AB-ISMS27 Medicinal Chemistry in the Discovery of Perampanel (Fycompa[®]), as a First-in-Class Orally Active Noncompetitive AMPA Receptor Antagonist
 ○Yoshihiko NORIMINE¹, Satoshi NAGATO¹, Koushi UENO¹, Koki KAWANO¹, Koichi ITO¹, Shigeki HIBI¹, Takahisa HANADA², Osamu TAKENAKA³, Masahiro YONAGA¹ (¹Medicinal Chemistry, ²Biopharmacology, and ³Drug Metabolism and Pharmacokinetics, Tsukuba Research Laboratories, Eisai Co., Ltd.)
- 28AB-ISMS28 Novel Epigenetic Enzyme Inhibitors for EHMT1/2
 ○Norimasa MORITA¹, Anita WEGERT¹, Ruben LEENDERS¹, Remco ZIJLMANS¹, Federica TRIVARELLI¹, Eddy DAMEN¹, Gerhard MÜLLER¹, Daniel MÜLLER², Carolin HEIDEMANN-DINGER², Michael KUBBUTAT² (¹Mercachem bv, ²ProQinase GmbH)
- 28AB-ISMS29 Novel CDK8 Inhibitors with Long Residence Time: New Opportunities for Cancer Treatment
 Pauline van MEURS¹, Eddy DAMEN¹, Johan VEERMAN¹, Norimasa MORITA¹, Holger WEBER², Frank TOTZKE², Jan E. EHLERT², Christoph SCHÄCHTELE², Michael H.G. KUBBUTAT²,
 ○Gerhard MÜLLER¹ (¹Mercachem bv, ²ProQinase GmbH)
- 28AB-ISMS30 Structural Basis to Dissect the Binding Affinity and Specificity of Human Galectin Inhibitors
 ○Chun-Hung Hans LIN¹ (¹Institute of Biological Chemistry, Academia Sinica)
- 28AB-ISMS31 Discovery of Novel ITK Type 1½ Inhibitors Using Fragment-based Drug Design
 ○Sae JIKIHARA¹, Takahiko YAMAMOTO¹, Kazuya YASUO¹, Maki HATTORI¹, Eriko MATSUOKA¹, Chiaki FUJIKOSHI¹, Kazuya KANO¹, Morio NAGIRA¹, Satoru ISHIDA¹, Ichiro HIKITA¹, Ken-ichi MATSUMURA¹, Hiroto YAMAGUCHI¹, Kenichi HIGASHINO¹ (¹Shionogi & Co., Ltd.)
- 28AB-ISMS32 Studies on Constitutive Androstane Receptor Activation of *Artemisia capillaris* and Coumarin Derivatives
 Ju-Ling CHEN¹, Pei-Ling HSU¹, Chen-Yuan CHIU², Shing-Hwa LIU², Tian-Shung WU³, Shin-Hun JUANG⁴,
 ○Hsin-Yi HUNG³ (¹School of Pharmacy, China Medical University, ²Institute of Toxicology, College of Medicine, National Taiwan University, ³School of Pharmacy, National Cheng Kung University, ⁴Department of Pharmacy, Tajen University)
- 28AB-ISMS33 ADLib[®] System: The Avian Cell-based Antibody Display System with Human Repertoire
 ○Tomoaki UCHIKI¹, Kenjiro ASAGOSHI¹, Hitomi MASUDA¹, Aki TAKAIWA¹, Atsushi SAWADA¹, Chika KOYAMA¹, Shigehisa KAWATA¹, Shunsuke MIYAI¹, Naoki TAKAHASHI¹, Ryohei ITO¹, Kazushi HIRANUKA¹, Shunsuke MORIYAMA¹, Takashi YABUKI¹, Shu-ichi HASHIMOTO¹ (¹Chiome Bioscience Inc.)
- 28AB-ISMS34 Discovery of 1,2,4-oxadiazolidine-3,5-dione Derivatives as Novel GPR40 Agonists
 ○Kenji NEGORO¹, Fumiyoshi IWASAKI¹, Yasuhiro YONETOKU¹, Kei OHNUKI¹, Toshio KUROSAKI¹, Kazuyuki KURAMOTO¹, Shigeru YOSHIDA¹, Hirotsugu TANAKA¹, Masaru HAYASHI¹, Hiroshi KAYAKIRI¹ (¹Astellas Pharma Inc.)
- 28AB-ISMS35 6-Arylpyrazine-2-carboxamides: A New Core for *Trypanosoma brucei* Inhibitors
 Raphaël RAHMANI¹, Kung BAN², Amy J. JONES³, Lori FERRINS¹, Danny GANAME², Melissa L. SYKES³, Vicky M. AVERY³, Karen L. WHITE⁴, Eileen RYAN⁴, Marcel KAISER^{5,6}, Susan A. CHARMAN⁴,
 ○Jonathan B. BAELL¹ (¹Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), ²The Walter and Eliza Hall Institute, ³Eskitis Institute for Drug Discovery, Griffith University, ⁴Centre for Drug Candidate Optimisation, Monash University, ⁵University of Basel, ⁶Swiss Tropical and Public Health Institute)
- 28AB-ISMS36 Hit to Lead Optimization of a New Class of Compound to Treat Human African Trypanosomiasis
 Stephanie RUSSELL¹, Raphaël RAHMANI², Amy J. JONES³, Arthur TOYNTON¹,
 Marzieh Rahmani KHAJOUEI¹, Harriet NEWSON¹, Lori FERRINS², Jeremy CHEANG¹, Rachel MCNICOLL¹, Don WEAVER^{4,5}, Brian SKELTON¹, Marcel KAISER⁶, Manu de RYCKER⁷, Kevin READ⁷, Susan A. CHARMAN^{2,8}, Vicky M. AVERY³, ○Jonathan B. BAELL², Matthew J. PIGGOTT¹ (¹School of Chemistry and Biochemistry, The University of Western Australia, ²Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, ³Eskitis Institute for Cell and Molecular Therapies, Griffith University, ⁴Department of Chemistry, Dalhousie University, ⁵Current address, Toronto Western Research Institute, ⁶Swiss Tropical and Public Health Institute, University of Basel, ⁷College of Life Sciences, University of Dundee, ⁸Centre for Drug Candidate Optimisation, Monash University)